CTOs on the Move

Forest Laboratories

www.frx.com

 
Forest Laboratories is a pharmaceutical company headquartered in New York City, US. The company's research and development spending has grown rapidly in recent years and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.frx.com
  • 909 3rd Ave
    New York, NY USA 10022
  • Phone: 212.421.7850

Executives

Name Title Contact Details

Similar Companies

Professional Gem Sciences Inc

Professional Gem Sciences Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Constab Pharmaceuticals

Constab Pharmaceuticals is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gencor Pacific

Gencor Pacific Incorporated is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vapotherm

Vapotherm Inc., is a publicly held corporation based in Exeter, New Hampshire that was founded in 1999 as a medical device manufacturer after creating the first heated and humidified high flow therapy nasal cannula system.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.